PADI2 and myeloid sarcoma: To address this hypothesis, we performed an ELISA to determine the prevalence of anti-PAD2 antibodies in the sera of individuals with diseases known or suspected to have an autoimmune process affecting the CNS: MS (n = 91), NMO (n = 32), and PTLD (n = 281).